Taysha outlines REVEAL 6-month interim analysis and FDA feedback in H1 2027 while targeting PPQ completion in Q4 2026

Data ReadoutREVEALNeutral

AI Analysis

Summary

Taysha Gene Therapies outlined plans for a 6-month interim analysis of the REVEAL trial in H1 2027 with accompanying FDA feedback, while targeting completion of PPQ in Q4 2026.

Clinical Trial Data

Outcome Details

6-month interim analysis expected in H1 2027 with FDA feedback; PPQ (Product Process Qualification) completion targeted for Q4 2026

Importance:5/10

Sentiment:

0.00

clinical trialinterim analysisregulatoryFDA feedback

Related Companies

$TSHA

Read the original article

Published by Seeking Alpha Healthcare on August 12, 2026 1:38 AM

Read Original